{
  "hash": "87873c23b9e5f7f7817a94c4c5823d56",
  "result": {
    "engine": "knitr",
    "markdown": "---\neditor_options: \n   chunk_output_type: console\n---\n\n\n\n# ACA Federal Upper Limits {#sec-acaful}\n\n__Affordable Care Act Federal Upper Limits (FUL)__ based on the weighted average of the most recently reported monthly __average manufacturer price (AMP)__ for pharmaceutical and therapeutically equivalent multiple source drug products that are available for purchase by retail community pharmacies on a nationwide basis.\n\n## Metadata\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code>  [ROWS] 1965434 \n [PAGES] 246 \n[FIELDS] 14 \n</code></pre>\n:::\n\n\n### Dictionary\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code><span style='color: #555555;'> 1</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>product_group</span>: <span style='color: #555555;'>The following methodology forms a Product Group:   Include all innovator (I) and non-innovator (N) pharmaceutically and therapeutically equivalent (A-rated) multiple source drugs when calculating the weighted average of monthly AMPs in a FUL Product Group;   Will not include single source (S) drugs when calculating the weighted average of monthly AMPs in a FUL Product Group;   Will not include formulations of the drug that are not rated by the FDA as pharmaceutically and therapeutically equivalent to the reference listed drug, (A-rated) in the calculation of the weighted average of monthly AMPs, or apply the FUL to those formulations that are not A-rated, e.g., B-rated drugs;   Will use the monthly AMP and AMP units reported and certified by manufacturers to calculate the weighted average of monthly AMPs in a FUL Product Group; and,   Will not include the AMP of a terminated drug in the weighted average of monthly AMPs.</span>\n\n<span style='color: #555555;'> 2</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ingredient</span>: <span style='color: #555555;'>The order of ingredients presented in the product labeleling.</span>\n\n<span style='color: #555555;'> 3</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>strength</span>: <span style='color: #555555;'>The strengths presented in the product labeleling.</span>\n\n<span style='color: #555555;'> 4</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>dosage</span>: <span style='color: #555555;'>The dosage form of the drug.</span>\n\n<span style='color: #555555;'> 5</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>route</span>: <span style='color: #555555;'>The route of administration of the drug.</span>\n\n<span style='color: #555555;'> 6</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>mdr_unit_type</span>: <span style='color: #555555;'>The unit type reported to the CMS Medicaid Drug Rebate Program.</span>\n\n<span style='color: #555555;'> 7</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>weighted_average_amps</span>: <span style='color: #555555;'>The calculated weighted average of the monthly amps for the group.</span>\n\n<span style='color: #555555;'> 8</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>aca_ful</span>: <span style='color: #555555;'>The calculated Federal Upper Limit (FUL) for the group.</span>\n\n<span style='color: #555555;'> 9</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>package_size</span>: <span style='color: #555555;'>Identifies the number of billing units in the package quantity from which the pharmacist dispenses.</span>\n\n<span style='color: #555555;'>10</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ndc</span>: <span style='color: #555555;'>The National Drug Code (NDC) is a numerical code maintained by the FDA that includes the labeler code, product code, and package code.</span>\n\n<span style='color: #555555;'>11</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>arated</span>: <span style='color: #555555;'>Identifies if the drug is an A-rated drug, (Yes or No).</span>\n\n<span style='color: #555555;'>12</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>multiplier_greater_than_175_percent_of_weighted_avg_of_amps</span>: <span style='color: #555555;'>ACA FUL equals the most current average retail community pharmacies' acquisition cost (NADAC) = Y   ACA FUL equals 175 percent of the weighted average of the most recently reported monthly AMPs = N   Note: All NDC-11s for a FUL Product Group are included in this file; however, only the (I) and (N), A-rated, multiple source drugs are used to calculate the weighted average of the most recently reported monthly AMPs in a FUL Product Group.</span>\n\n<span style='color: #555555;'>13</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>year</span>: <span style='color: #555555;'>The year in which the FUL was calculated.</span>\n\n<span style='color: #555555;'>14</span> <span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>month</span>: <span style='color: #555555;'>The month in which the FUL was calculated.</span>\n</code></pre>\n:::\n\n\n## Data\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code><span style='color: #555555;'># A tibble: 8,000 × 14</span>\n   product_group ingredient          strength dosage route mdr_unit_type aca_ful\n   <span style='color: #555555; font-style: italic;'><chr></span>         <span style='color: #555555; font-style: italic;'><chr></span>               <span style='color: #555555; font-style: italic;'><chr></span>    <span style='color: #555555; font-style: italic;'><chr></span>  <span style='color: #555555; font-style: italic;'><fct></span> <span style='color: #555555; font-style: italic;'><fct></span>           <span style='color: #555555; font-style: italic;'><dbl></span>\n<span style='color: #555555;'> 1</span> 1165          NYSTATIN            500000U  TABLET ORAL  TAB            0.442 \n<span style='color: #555555;'> 2</span> 4486          OLMESARTAN MEDOXOM… 20MG     TABLET ORAL  TAB            0.673 \n<span style='color: #555555;'> 3</span> 2662          RIVASTIGMINE TARTR… 3MG      CAPSU… ORAL  CAP            0.330 \n<span style='color: #555555;'> 4</span> 1912          QUINAPRIL HYDROCHL… 5MG      TABLET ORAL  TAB            0.131 \n<span style='color: #555555;'> 5</span> 8824          MONTELUKAST SODIUM  10MG     TABLET ORAL  TAB            0.093<span style='text-decoration: underline;'>5</span>\n<span style='color: #555555;'> 6</span> 3457          METFORMIN HCL       1000 MG  TABLET ORAL  TAB            0.031<span style='text-decoration: underline;'>2</span>\n<span style='color: #555555;'> 7</span> 3930          TOLTERODINE TARTRA… 4 MG     CAP E… ORAL  CAP            1.95  \n<span style='color: #555555;'> 8</span> 1887          DILTIAZEM HYDROCHL… 360MG    CAPSU… ORAL  CAP            0.615 \n<span style='color: #555555;'> 9</span> 1938          FENOFIBRATE         134MG    CAPSU… ORAL  CAP            0.432 \n<span style='color: #555555;'>10</span> 857           INDAPAMIDE          2.5MG    TABLET ORAL  TAB            0.211 \n<span style='color: #555555;'># ℹ 7,990 more rows</span>\n<span style='color: #555555;'># ℹ 7 more variables: package_size <int>, ndc <chr>, arated <int>, year <int>,</span>\n<span style='color: #555555;'>#   month <int>, amp_wt_avg <dbl>, gt_175pc_amp_wt_avg <int></span>\n</code></pre><pre class=\"r-output\"><code>obs: 8000 \ncols: 14 \n\n----- Numeric -----\n             col n_missng p_complt n_unique    mean        p0      p25     p50\n1        aca_ful        0        1     1234    1.43    0.0033    0.099    0.25\n2   package_size        0        1       71  227.45         1       30     100\n3         arated        0        1        2    0.99         0        1       1\n4           year        0        1        1    2019      2019     2019    2019\n5          month        0        1        2       2         2        2       2\n6     amp_wt_avg        0        1     1235    0.75    0.0019    0.049    0.12\n7 gt_175pc_mp_w_        0        1        2    0.38         0        0       0\n      p75    p100   iqr      sd  hist\n1    0.84   127.3  0.74    5.56 ▇▁▁▁▁\n2     100   28000    70  557.17 ▇▁▁▁▁\n3       1       1     0   0.094 ▁▁▁▁▇\n4    2019    2019     0       0 ▁▁▇▁▁\n5       2      11     0    0.17 ▇▁▁▁▁\n6    0.42    72.7  0.37    3.08 ▇▁▁▁▁\n7       1       1     1    0.48 ▇▁▁▁▅\n\n----- Categorical -----\n            col n_missng p_complt n_unique n_levels              min\n1 product_group        0        1     1237       NA            10036\n2    ingredient        0        1      466       NA ABACAVIR SULFATE\n3      strength        0        1      389       NA       .025MG/24H\n4        dosage        0        1       66       NA       ADH. PATCH\n5         route        0        1       14       14           DENTAL\n6 mdr_unit_type        0        1        6        6              CAP\n7           ndc        0        1     8000       NA    00002-3231-30\n            max\n1           992\n2    ZONISAMIDE\n3          90MG\n4          VIAL\n5       VAGINAL\n6           TDP\n7 99207-0010-10\n</code></pre>\n:::\n\n\n### Distribution\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code>Variable            |    Mean |     SD |   IQR |              Range | Skewness\n------------------------------------------------------------------------------\naca_ful             |    1.43 |   5.56 |  0.74 | [3.28e-03, 127.26] |    13.10\npackage_size        |  227.45 | 557.17 | 70.00 |   [1.00, 28000.00] |    21.21\narated              |    0.99 |   0.09 |  0.00 |       [0.00, 1.00] |   -10.48\nyear                | 2019.00 |   0.00 |  0.00 | [2019.00, 2019.00] |         \nmonth               |    2.00 |   0.17 |  0.00 |      [2.00, 11.00] |    51.62\namp_wt_avg          |    0.75 |   3.08 |  0.37 |  [1.87e-03, 72.72] |    13.91\ngt_175pc_amp_wt_avg |    0.38 |   0.48 |  1.00 |       [0.00, 1.00] |     0.51\n\nVariable            | Kurtosis |    n | n_Missing\n-------------------------------------------------\naca_ful             |   236.32 | 8000 |         0\npackage_size        |   849.35 | 8000 |         0\narated              |   107.75 | 8000 |         0\nyear                |          | 8000 |         0\nmonth               |  2663.33 | 8000 |         0\namp_wt_avg          |   264.56 | 8000 |         0\ngt_175pc_amp_wt_avg |    -1.74 | 8000 |         0\n</code></pre>\n:::\n\n\n\n::: {.cell layout-ncol=\"2\" layout-align=\"center\"}\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-1.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-2.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-3.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-4.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-5.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-6.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-7.png){fig-align='center' width=70%}\n:::\n:::\n\n",
    "supporting": [
      "caid_acaful_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}